ASCO 2020 Prostate Cancer

Viewing 1-20 of 71 articles

ASCO 2020: A Phase II Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

ASCO 2020: Evaluation of a Mainstream Model of Genetic Testing for Men with Prostate Cancer

ASCO 2020: Genitourinary Cancers Highlights – Prostate, Testicular, and Penile Cancers

ASCO 2020: Short-Term Adjuvant Versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Phase III Trials

ASCO 2020: CYCLONE 2: A Phase II, Randomized, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or Without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO 2020: Quality of Life for the Treatment Sequence of Abiraterone Acetate plus Prednisone Followed by Enzalutamide Versus the Opposite Sequence for Metastatic Castration-Resistant Prostate Cancer: Results from a Phase II Randomized Clinical Trial

ASCO 2020: Association Between BRCA2 Status and Histologic Variants Intraductal and Cribriform Histology in Prostate Cancer

ASCO 2020: Clinical Outcomes and Markers of Treatment Response in a Randomized Phase II Study of Androgen Deprivation Therapy with or Without Palbociclib in RB-Intact Metastatic Hormone-Sensitive Prostate Cancer

ASCO 2020: Discussant: Promising Therapeutic Targets in Prostate Cancer

ASCO 2020: Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to Androgen Deprivation Therapy for Non-metastatic Castration-Resistant Prostate Cancer

ASCO 2020: Cost-Effectiveness of Novel Antiandrogens for Treatment of Nonmetastatic Castrate-Resistant Prostate Cancer

ASCO 2020: Discussant: Advanced Prostate Cancer: Putting Survival Into Perspective

ASCO 2020: Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study: A Canadian Cancer Trials Group Phase 2 Umbrella Trial for MCRPC (IND223/IND224)

ASCO 2020: Ensuring Cancer Research Progress During a Global Pandemic

ASCO 2020: Looking Back on COVID-19 in Order to Move Forward

ASCO 2020: TERAVOLT – Thoracic Cancers International COVID-19 Collaboration: Impact of Cancer Therapy and COVID-19 Therapy on Survival

ASCO 2020: Safety Outcomes of Darolutamide Versus Apalutamide and Enzalutamide in nmCRPC: Matching-Adjusted Indirect Comparisons

ASCO 2020: Cabazitaxel vs. Enazlutamide/arbiraterone in CARD Eligible mCRPC Patients with or Without Germline HRR Defects

ASCO 2020: Cancer Care in the Time of COVID: Assessing Impact and Future Directions

ASCO 2020: Molecular Determinants of Outcome for Metastatic Castration-Sensitive Prostate Cancer with Addition of Apalutamide or Placebo to Androgen Deprivation Therapy in TITAN

1
2
3
4